(State or Other Jurisdiction of Incorporation) | (Commission File Number) | (IRS Employer Identification No.) |
(Address of Principal Executive Offices) | (Zip Code) |
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) | |||||
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) | |||||
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) | |||||
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Title of each class | Trading Symbol(s) | Name of each exchange on which registered | ||||||||||||
Exhibit No. | Description | |||||||
99.1 | ||||||||
99.2 | ||||||||
104 | Cover Page Interactive Data File (embedded within the Inline XBRL document) | |||||||
Acumen Pharmaceuticals, Inc. | ||||||||
Dated: November 13, 2023 | By: | /s/ Matthew Zuga | ||||||
Matthew Zuga Chief Financial Officer and Chief Business Officer |
September 30, 2023 | December 31, 2022 | ||||||||||
(unaudited) | |||||||||||
ASSETS | |||||||||||
Current assets | |||||||||||
Cash and cash equivalents | $ | 94,917 | $ | 130,101 | |||||||
Marketable securities, short-term | 120,517 | 47,504 | |||||||||
Prepaid expenses and other current assets | 3,164 | 2,724 | |||||||||
Total current assets | 218,598 | 180,329 | |||||||||
Marketable securities, long-term | 67,270 | 15,837 | |||||||||
Restricted cash | 189 | — | |||||||||
Property and equipment, net | 123 | 165 | |||||||||
Right-of-use asset | 2 | 105 | |||||||||
Other assets | 189 | 151 | |||||||||
Total assets | $ | 286,371 | $ | 196,587 | |||||||
LIABILITIES AND STOCKHOLDERS’ EQUITY | |||||||||||
Current liabilities | |||||||||||
Accounts payable | $ | 1,362 | $ | 1,640 | |||||||
Accrued clinical trial expenses | 1,566 | 2,717 | |||||||||
Accrued expenses and other current liabilities | 3,168 | 3,350 | |||||||||
Operating lease liability | 2 | 105 | |||||||||
Total current liabilities | 6,098 | 7,812 | |||||||||
Total liabilities | 6,098 | 7,812 | |||||||||
Commitments and contingencies | |||||||||||
Stockholders’ equity | |||||||||||
Preferred stock, $0.0001 par value; 10,000,000 shares authorized and no shares issued and outstanding as of September 30, 2023 and December 31, 2022 | — | — | |||||||||
Common stock, $0.0001 par value; 300,000,000 shares authorized as of September 30, 2023 and December 31, 2022; 57,910,461 and 41,025,062 shares issued and outstanding as of September 30, 2023 and December 31, 2022 | 6 | 4 | |||||||||
Additional paid-in capital | 487,077 | 359,949 | |||||||||
Accumulated deficit | (206,301) | (170,427) | |||||||||
Accumulated other comprehensive loss | (509) | (751) | |||||||||
Total stockholders’ equity | 280,273 | 188,775 | |||||||||
Total liabilities and stockholders’ equity | $ | 286,371 | $ | 196,587 |
Three Months Ended September 30, | Nine Months Ended September 30, | ||||||||||||||||||||||
2023 | 2022 | 2023 | 2022 | ||||||||||||||||||||
Operating expenses | |||||||||||||||||||||||
Research and development | $ | 11,179 | $ | 8,309 | $ | 29,025 | $ | 21,615 | |||||||||||||||
General and administrative | 4,860 | 3,062 | 13,627 | 9,374 | |||||||||||||||||||
Total operating expenses | 16,039 | 11,371 | 42,652 | 30,989 | |||||||||||||||||||
Loss from operations | (16,039) | (11,371) | (42,652) | (30,989) | |||||||||||||||||||
Other income (expense) | |||||||||||||||||||||||
Interest income, net | 3,124 | 663 | 6,840 | 1,000 | |||||||||||||||||||
Other expense, net | (42) | (2) | (62) | (1) | |||||||||||||||||||
Total other income | 3,082 | 661 | 6,778 | 999 | |||||||||||||||||||
Net loss | (12,957) | (10,710) | (35,874) | (29,990) | |||||||||||||||||||
Other comprehensive gain (loss) | |||||||||||||||||||||||
Unrealized gain (loss) on marketable securities | 137 | — | 242 | (734) | |||||||||||||||||||
Comprehensive loss | $ | (12,820) | $ | (10,710) | $ | (35,632) | $ | (30,724) | |||||||||||||||
Net loss per common share, basic and diluted | $ | (0.24) | $ | (0.26) | $ | (0.79) | $ | (0.74) | |||||||||||||||
Weighted-average shares outstanding, basic and diluted | 54,229,630 | 40,502,860 | 45,474,953 | 40,491,181 |
Nine Months Ended September 30, | |||||||||||
2023 | 2022 | ||||||||||
Cash flows from operating activities | |||||||||||
Net loss | $ | (35,874) | $ | (29,990) | |||||||
Adjustments to reconcile net loss to net cash used in operating activities: | |||||||||||
Depreciation | 42 | 20 | |||||||||
Stock-based compensation expense | 4,511 | 2,173 | |||||||||
Amortization of premiums and accretion of discounts on marketable securities, net | (1,344) | 575 | |||||||||
Amortization of right-of-use asset | 103 | 100 | |||||||||
Changes in operating assets and liabilities: | |||||||||||
Prepaid expenses and other current assets | (436) | 2,058 | |||||||||
Other assets | (38) | (78) | |||||||||
Accounts payable | (278) | 996 | |||||||||
Accrued clinical trial expenses | (1,151) | 1,358 | |||||||||
Operating lease liability | (103) | (100) | |||||||||
Accrued expenses and other current liabilities | (182) | (1,062) | |||||||||
Net cash used in operating activities | (34,750) | (23,950) | |||||||||
Cash flows from investing activities | |||||||||||
Purchases of marketable securities | (178,857) | (12,129) | |||||||||
Proceeds from maturities and sales of marketable securities | 55,997 | 71,860 | |||||||||
Proceeds from sale of property and equipment | 3 | — | |||||||||
Purchases of property and equipment | (7) | (126) | |||||||||
Net cash provided by (used in) investing activities | (122,864) | 59,605 | |||||||||
Cash flows from financing activities | |||||||||||
Proceeds from issuance of common stock, net of issuance costs | 122,294 | — | |||||||||
Proceeds from exercise of stock options | 325 | 19 | |||||||||
Payments for deferred offering costs | — | (296) | |||||||||
Net cash provided by (used in) financing activities | 122,619 | (277) | |||||||||
Net change in cash and cash equivalents and restricted cash | (34,995) | 35,378 | |||||||||
Cash and cash equivalents and restricted cash at the beginning of the period | 130,101 | 122,162 | |||||||||
Cash and cash equivalents and restricted cash at the end of the period | $ | 95,106 | $ | 157,540 |
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
J%&DHQ(7BM!!)< %%;X,+5[2D]3J>WJ M!I.:C3#[R 1'XI3;JT!"O"$Q2K;>,1>2:37Y: =A 19.GD.[@[M[J>>1%7[OC5KNM;E7! MMM?25FY=P(ILVB 4B1*,@8!@4QD(:F8!CH;,&2.23=N0 #,PF,:P7-"DR%#Y M:*I=,;# O>I1VJ4;U$XFPDT-4)NJ:S$].K*YAQ#A)V=DP &P# #8 M+;O[6*!3[_=OJ9@S*?;% )G#[XBEV*\*8H^[D)1RQS4O)TC2LB]V74 N]?TW!/':YJFN:4R[IS%M5EUC%)7!" M 954XF'( #,>@,!:8YGZ\1,+0FHNA(6H#JMX1/H6)C.B=+*90HR:(E(\I>[[ MZQ?[7>7#LFV6U54E;[7[!4S:.JJOI]*E:DF(.7J^17E:?0D4)=*-62J*HIEL MFB21;)JZDR$/F4 U9=&(_6]7ZDU&PB6K4TM]AM>9((0(*A"/52#@2+.U-T_1 MZ.XIVFL):<4F!(*C$1!A>2,0/ K3$$;0<"#B+.E M\J?FH6?YG%DR5/ "PHN^M$,V#.]EFE7P+/Z9E5B@BG4],F7,#J;MY4+@AC,7 MF0G;G$6SG2L0!4KGKG0]0T74N"[%RF.DEEZ%RAYJM@<3Y0V]H78&/2VJ)34L MEQ&X(GD <1O:#YR=Z#L.S WXK(>U\C^7C9R'\R]UQ^W6%/!^M@S\@?HNH?.& MO@&PXYK_ "^3_@E?"%K\]'_HQT8%D?\ R:TXA_\ 1VO.P,[3>U2V]' Y- MIU%54?I:Q%E!'82?QA!P4H=GS1?B;JP\V^87M!U>E:*O]!;5"8<2?6*!]4DC M%"3VS@I5V ,5Z]TE2,9.K(>.:N"*(4_#N0>K@8."1TZ=F47(!\])@01;E P^ M0!S#W,6YT3+*E*:]-/\ 52M<;[H)2G$[A>3:JNHL[\ZS*M)*G2F O)4M4 M-Y-PM2MN M#ICC&UQ=,TFJT32TA2ZNZ79IEB!]" M)*@W';PP0@'HA@!8-ZGJ=A2\>9X[$%'"@&(Q9%-DJ[6 /)[HD03SS.?R '1Y M1 ,9,LN/KX;?C.P#?]P;;;ZE46: Z>RG>?N#:;=)Y?UVW\5N71CIMZ(M M+H0 203$=)"E6:*HD .D16Z 9\65:'#T-]%H,S./3$Z79@Q6L0^X!N&P69GV[6=DK M]WGH*UD<54$:CF4C3KM(HF&,I:.^75'(F$.@G!BT3E((^58Y \HX\5]!Z4F- M;:MDM-,1R3#PXBAY#*>LZKQ(! ](@;;2>D4Y=5J34BB,%JZQW)%ZC[GOV9NW ML[F*%V ;,KKWWD&[%K$6?M\#"@Z:$Y$4IJK56Z%.6ZI!HD)R&4+(SSAHB<"9 MF(V!13+(@X]A-%Z7%6JDCIFFHXE.23NR^T-[Z1-VZJ/&N)Z1J^_5 MSJN4BK64_%QI,U9F?=UG*N)A)J0 F89H#&C=.) J,^. TF. M4(8;1%U1.Q(0 @GTM]@+I,,N59W4=843)RIXJU8E3JU00(;25$JQ\G=:TSG< M\USEB\R3:$E0ULZNN:E?RUU9Q-?V@7J.T500\>_67$L'6=*/IM151O%L9^FG MAUN(?,@O/HZ0A'+;0NM-'U_O,XVS[+?;*'
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end
PGS,X6023/:W<,J$Y$JG(^M?L%_P $?/C;_:%[IGA>6\^YL^5F]?\
M]5?D!/&'*L>QK[ _X)4?&E_"_P <(+6>Z(1/*X8\?>->3G>'6)P$E;8Z<'4]
ME75S^B2&1)AYB."/45#J&HV=E"TT]PJ;1D[C7"^ OBOIU_X&;Q"T\;*NW/S>
MH->/_&K]INVE>2TL)0A;*C:37X1FF;87*T^>6JZ'TE2O&G&YZ)\5OV@;7PG;
MNEG M);'2V=G#96T=O$B@1H%&T8Z"GAB_L[_ +1'C'X'^*K&3P]+LB6Z#2'S",#->;G634,TH-->
M\CLRW,JN"JIIZ']@_A[7+3Q%I%OJ]D
Cover |
Nov. 13, 2023 |
---|---|
Cover [Abstract] | |
Document Type | 8-K |
Document Period End Date | Nov. 13, 2023 |
Entity Registrant Name | Acumen Pharmaceuticals, Inc. |
Entity Incorporation, State or Country Code | DE |
Entity File Number | 001-40551 |
Entity Tax Identification Number | 36-4108129 |
Entity Address, Address Line One | 427 Park St. |
Entity Address, City or Town | Charlottesville |
Entity Address, State or Province | VA |
Entity Address, Postal Zip Code | 22902 |
City Area Code | 434 |
Local Phone Number | 297-1000 |
Written Communications | false |
Soliciting Material | false |
Pre-commencement Tender Offer | false |
Pre-commencement Issuer Tender Offer | false |
Title of 12(b) Security | Common Stock, $0.0001 par value |
Trading Symbol | ABOS |
Security Exchange Name | NASDAQ |
Entity Emerging Growth Company | true |
Entity Ex Transition Period | false |
Entity Central Index Key | 0001576885 |
Amendment Flag | false |
%^@2O&+(=/EB>N$_NG_A.
M\SQ-LPRKZ'8;9;#%ZI9E\!>/AG$##RP/9'I;K?%NXQ/R^AQ@/7UM0K"=XI.(
M[12O-2#QNH%'GL>[C>4!#ZP+V.Q _G@>F*FX3YI"5S%NV G&D3S'$)C%^(QF
M&5*=##[Q_F"G)$WS/(X %F>0IA@"IQ%', ; 4/2='@//GL?)=-[*CG_5U/\
M!%!+ P04 " !].FU7EXJ[', 3 @ "P %]R96QS+RYR96QSG9*Y
M;L,P#$!_Q=">, ?0(8@S9?$6!/D!5J(/V!(%BD6=OZ_:I7&0"QEY/3P2W!YI
M0.TXI+:+J1C]$%)I6M6X 4BV)8]ISI%"KM0L'C6'TD!$VV-#L%HL/D N&6:W
MO606IW.D5XA &UL4$L! A0#% @ ?3IM
M5P[\IJ5:! $A$ !@ ("!#0@ 'AL+W=O
^ .B96LGX4CC)%( QT
M=^8+J0$4KA$M!V/1K9D7H4G27T/S-* I);^&YFE 4TK]DD'SE*W^S]22PPN<
M<"38A;+YE^Y_KQJL7J,\:YQG>.@#)E:*.%%X;[! [-: